{
    "clinical_study": {
        "@rank": "104044", 
        "arm_group": [
            {
                "arm_group_label": "MK-3102", 
                "arm_group_type": "Experimental", 
                "description": "MK-3102 25 mg capsule administered orally once a week for 24 weeks.  Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day)."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to MK-3102 capsule administered orally once a week for 24 weeks.  Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day)."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will examine the safety and efficacy of the addition of MK-3102 in participants\n      with type 2 diabetes mellitus with inadequate glycemic control on metformin and\n      sulfonylurea. The primary hypothesis is that after 24 weeks, the addition of treatment with\n      MK-3102 provides a greater reduction in hemoglobin A1c (A1C) compared with the addition of\n      placebo."
        }, 
        "brief_title": "Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM4)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with type 2 diabetes mellitus\n\n          -  Currently taking stable doses of metformin (>=1500 mg/day) and sulfonylurea\n\n          -  Male, or female not of reproductive potential or female of reproductive potential who\n             agrees to remain abstinent or use (or have their partner use) 2 methods of acceptable\n             contraception to prevent pregnancy during the study and for 21 days after the last\n             dose of study drug\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  Treated with any antihyperglycemic agent therapies other than the protocol-required\n             sulfonylurea and metformin within 12 weeks prior to study participation or with\n             MK-3102 at any time prior to study participation.\n\n          -  History of hypersensitivity to a dipeptidyl peptidase IV (DPP-4) inhibitor\n\n          -  On a weight loss program and is not in the maintenance phase; or has been on a weight\n             loss medication in the past 6 months; or has undergone bariatric surgery within 12\n             months prior to study participation.\n\n          -  Is on or likely to require treatment for >=2 consecutive weeks or repeated courses of\n             corticosteroids (inhaled, nasal or topical corticosteroids are permitted)\n\n          -  Currently being treated for hyperthyroidism or is on thyroid replacement therapy and\n             has not been on a stable dose for at least 6 weeks\n\n          -  Medical history of active liver disease (other than non-alcoholic hepatic steatosis),\n             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic\n             gallbladder disease\n\n          -  Human immunodeficiency virus (HIV)\n\n          -  New or worsening coronary heart disease, congestive heart failure, myocardial\n             infarction, unstable angina, coronary artery intervention, stroke, or transient\n             ischemic neurological disorder within the past 3 months\n\n          -  Poorly controlled hypertension\n\n          -  History of malignancy <=5 years prior to study participation, except for adequately\n             treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n\n          -  Clinically important hematological disorder (such as aplastic anemia,\n             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n          -  Pregnant or breast feeding, or is expecting to conceive or donate eggs during the\n             trial, including 21 days following the last dose of study drug\n\n          -  Current user of recreational or illicit drugs or has had a recent history of drug\n             abuse or routinely consumes >2 alcoholic drinks per day or >14 drinks per week, or\n             engages in binge drinking\n\n          -  Donated blood products within 8 weeks of study participation, or intends to donate\n             blood products during the study or has received or anticipates receiving blood\n             products within 12 weeks prior to study participation or during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704261", 
            "org_study_id": "3102-022", 
            "secondary_id": "2012-002612-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-3102", 
                "description": "MK-3102 25 mg capsule administered orally once a week", 
                "intervention_name": "MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo to MK-3102 capsule administered orally once a week", 
                "intervention_name": "Matching placebo to MK-3012", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Placebo"
                ], 
                "description": "Open-label glimepiride tablet(s) administered orally once daily for a total daily dose >=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.", 
                "intervention_name": "Glimepiride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Amaryl\u00ae", 
                    "Glimy"
                ]
            }, 
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Placebo"
                ], 
                "description": "Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose >=1500 mg", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fortamet\u00ae", 
                    "Glucophage\u00ae", 
                    "Glucophage\u00ae XR", 
                    "Glumetza\u00ae", 
                    "Riomet\u00ae"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in hemoglobin A1c (A1C)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percentage of Participants Who Experienced at Least One Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 27"
            }, 
            {
                "measure": "Percentage of Participants Who Discontinued from the Study Due to an Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Korea, Republic of", 
                "Russian Federation", 
                "South Africa", 
                "Poland", 
                "Romania"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704261"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percentage of participants attaining A1C glycemic goals of <7% and <6.5%", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}